259 related articles for article (PubMed ID: 27129117)
1. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
Krishnaswami S; Wang T; Yuan Y; Alvey CW; Checchio T; Peterson M; Shi H; Riese R
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
[TBL] [Abstract][Full Text] [Related]
4. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
Klamerus KJ; Alvey C; Li L; Feng B; Wang R; Kaplan I; Shi H; Dowty ME; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):499-507. PubMed ID: 27129125
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
Krishnaswami S; Chow V; Boy M; Wang C; Chan G
J Clin Pharmacol; 2014 Jan; 54(1):46-52. PubMed ID: 24030917
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Huang F; Luo ZC
Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
[TBL] [Abstract][Full Text] [Related]
10. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Ruperto N; Brunner HI; Zuber Z; Tzaribachev N; Kingsbury DJ; Foeldvari I; Horneff G; Smolewska E; Vehe RK; Hazra A; Wang R; Mebus CA; Alvey C; Lamba M; Krishnaswami S; Stock TC; Wang M; Suehiro R; Martini A; Lovell DJ; ;
Pediatr Rheumatol Online J; 2017 Dec; 15(1):86. PubMed ID: 29282090
[TBL] [Abstract][Full Text] [Related]
12. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Miyoshi S; Krishnaswami S; Toyoizumi S; Nakamura H; Zwillich SH
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):11-20. PubMed ID: 31713350
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Trueman S; Mohamed MF; Feng T; Lacerda AP; Marbury T; Othman AA
J Clin Pharmacol; 2019 Sep; 59(9):1188-1194. PubMed ID: 30973649
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
[TBL] [Abstract][Full Text] [Related]
18. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
[TBL] [Abstract][Full Text] [Related]
19. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; O'Gorman M; Tripathy S; Dowty ME; Wang L; Malhotra BK
J Clin Pharmacol; 2021 Oct; 61(10):1311-1323. PubMed ID: 33749838
[TBL] [Abstract][Full Text] [Related]
20. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
